These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 16809318)

  • 1. Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1.
    Krachmarov CP; Honnen WJ; Kayman SC; Gorny MK; Zolla-Pazner S; Pinter A
    J Virol; 2006 Jul; 80(14):7127-35. PubMed ID: 16809318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence.
    Honnen WJ; Krachmarov C; Kayman SC; Gorny MK; Zolla-Pazner S; Pinter A
    J Virol; 2007 Feb; 81(3):1424-32. PubMed ID: 17121806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.
    Gorny MK; Williams C; Volsky B; Revesz K; Wang XH; Burda S; Kimura T; Konings FA; Nádas A; Anyangwe CA; Nyambi P; Krachmarov C; Pinter A; Zolla-Pazner S
    J Virol; 2006 Jul; 80(14):6865-72. PubMed ID: 16809292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.
    Pinter A; Honnen WJ; D'Agostino P; Gorny MK; Zolla-Pazner S; Kayman SC
    J Virol; 2005 Jun; 79(11):6909-17. PubMed ID: 15890930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens.
    Derby NR; Gray S; Wayner E; Campogan D; Vlahogiannis G; Kraft Z; Barnett SW; Srivastava IK; Stamatatos L
    Virology; 2007 Sep; 366(2):433-45. PubMed ID: 17560621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.
    Pinter A; Honnen WJ; He Y; Gorny MK; Zolla-Pazner S; Kayman SC
    J Virol; 2004 May; 78(10):5205-15. PubMed ID: 15113902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.
    Krachmarov C; Pinter A; Honnen WJ; Gorny MK; Nyambi PN; Zolla-Pazner S; Kayman SC
    J Virol; 2005 Jan; 79(2):780-90. PubMed ID: 15613306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.
    Li L; Wang XH; Williams C; Volsky B; Steczko O; Seaman MS; Luthra K; Nyambi P; Nadas A; Giudicelli V; Lefranc MP; Zolla-Pazner S; Gorny MK
    Mol Immunol; 2015 Aug; 66(2):364-74. PubMed ID: 25965315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.
    Gorny MK; Revesz K; Williams C; Volsky B; Louder MK; Anyangwe CA; Krachmarov C; Kayman SC; Pinter A; Nadas A; Nyambi PN; Mascola JR; Zolla-Pazner S
    J Virol; 2004 Mar; 78(5):2394-404. PubMed ID: 14963135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
    Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
    J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci.
    He Y; Honnen WJ; Krachmarov CP; Burkhart M; Kayman SC; Corvalan J; Pinter A
    J Immunol; 2002 Jul; 169(1):595-605. PubMed ID: 12077293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.
    Gorny MK; Wang XH; Williams C; Volsky B; Revesz K; Witover B; Burda S; Urbanski M; Nyambi P; Krachmarov C; Pinter A; Zolla-Pazner S; Nadas A
    Mol Immunol; 2009 Feb; 46(5):917-26. PubMed ID: 18952295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope.
    Upadhyay C; Mayr LM; Zhang J; Kumar R; Gorny MK; Nádas A; Zolla-Pazner S; Hioe CE
    J Virol; 2014 Nov; 88(21):12853-65. PubMed ID: 25165106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.
    Gorny MK; Williams C; Volsky B; Revesz K; Cohen S; Polonis VR; Honnen WJ; Kayman SC; Krachmarov C; Pinter A; Zolla-Pazner S
    J Virol; 2002 Sep; 76(18):9035-45. PubMed ID: 12186887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
    Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
    J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.
    Kong R; Louder MK; Wagh K; Bailer RT; deCamp A; Greene K; Gao H; Taft JD; Gazumyan A; Liu C; Nussenzweig MC; Korber B; Montefiori DC; Mascola JR
    J Virol; 2015 Mar; 89(5):2659-71. PubMed ID: 25520506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities.
    Alsmadi O; Tilley SA
    J Virol; 1998 Jan; 72(1):286-93. PubMed ID: 9420226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies.
    Cardozo T; Swetnam J; Pinter A; Krachmarov C; Nadas A; Almond D; Zolla-Pazner S
    AIDS Res Hum Retroviruses; 2009 Apr; 25(4):441-50. PubMed ID: 19320565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.